Delta peritoneal cancer index (ΔPCI): A new dynamic prognostic parameter for survival in patients with colorectal peritoneal metastases

Hentzen, Judith E K R; Plas, Willemijn Y. van der; Kuipers, H.; Ramcharan, Swades; Been, Lukas B.; Hoogwater, Frederik J.H.; Ginkel, Robert J. van; Dam, Gooitzen M. van; Hemmer, Patrick H. J.; Kruijff, Schelto

doi:10.1016/j.ejso.2019.11.515

Cited by 4 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another study developed the delta PCI, describing the change in PCI score between diagnostic laparoscopy and explorative laparotomy during cytoreductive surgery and HIPEC. 47 Comparably, a larger delta PCI was independently associated with impaired overall survival. Both studies suggest that the increase in PCI score during a certain period may be used as a marker for the aggressiveness of tumor biology.…”

Section: Other Clinicopathological Factorsmentioning

confidence: 95%

Effective Strategies to Predict Survival of Colorectal Peritoneal Metastases Patients Eligible for Cytoreductive Surgery and HIPEC

Simkens¹,

Wintjens²,

Rovers

et al. 2021

CMAR

View full text Add to dashboard Cite

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), often combined with systemic therapy, can be offered to selected colorectal peritoneal metastases (PM) patients. However, clinical heterogeneity and the lack of high-level evidence challenges determination of the correct treatment strategy. This review aims to provide an overview of current strategies to predict survival of colorectal PM patients treated with CRS and HIPEC, guiding clinicians to select a suitable treatment-strategy and to inform patients about their prognosis. First, the prognostic relevance of several clinicopathological prognostic factors, such as extent of PM, location of primary tumor, histology type, and the presence of lymph node or liver metastases will be discussed. Subsequently, special attention will be given to recent developments in several aspects of tumor biology such as RAF/RAS mutations, circulating tumor DNA, immunoprofiling, and consensus molecular subtypes. Finally, currently available prognostic models to predict survival will be evaluated, concluding these models perform moderate to good, but most of them partly rely on intra-operative data. New insights in tumor biology, as well as the reliable assessment of extent of peritoneal disease by diffusion weighted MRI pose promising opportunities to establish an adequate and clinically meaningful preoperative prognostic model in the near future.

show abstract

Section: Other Clinicopathological Factorsmentioning

confidence: 95%

Effective Strategies to Predict Survival of Colorectal Peritoneal Metastases Patients Eligible for Cytoreductive Surgery and HIPEC

Simkens¹,

Wintjens²,

Rovers

et al. 2021

CMAR

View full text Add to dashboard Cite

show abstract

“…Irrespective of the incriminated theory, the authors demonstrated that a higher delta PCI value was inversely correlated with the likelihood of achieving a long-term survival rate. The authors concluded that cases presenting a delta PCI value ≥10 should be rather referred to the medical oncologist than to cytoreductive surgery and HIPEC; however, no significant correlation could be found between the presence and number of liver metastases and delta PCI (33).…”

Section: Patient Selection For Hipecmentioning

confidence: 96%

“…Regarding PCI values and the likelihood of successful treatment Hentzen et al (33) introduced a hypothesis, delta PCI, which seems to be a more reliable tool in order to identify cases that may benefit most from debulking and HIPEC. Authors of that study considered all patients as potential candidates for debulking and HIPEC.…”

Section: Patient Selection For Hipecmentioning

confidence: 99%

Determination of whether HIPEC is beneficial in patients with synchronous peritoneal and liver metastases from colorectal cancer (Review)

Bacalbaşa

Bălescu²,

Crețoiu

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

Peritoneal carcinomatosis, as well as the presence of liver metastases from colorectal cancer, has been long considered as the sign of a systemic disease, transforming the patient into a candidate for palliation and best supportive care. However, in recent decades, progress in the field of medical and surgical oncology has allowed scientists worldwide to produce curative therapeutic strategies for these cases such as hyperthermic intraperitoneal chemotherapy (HIPEC) or extended liver resection. In addition, the association of these two therapies has also been performed with encouraging results. The aim of the current study was to review articles published thus far in regard to the association of these two therapeutic strategies, in order to identify which cases can benefit the most, which is the most efficient agent or combination of agents, and whether these types of therapy should be performed as monotherapy or as a two-stage procedure. Contents

show abstract

“…В исследовании GOG172 [18] проведен подгрупповой анализ, показавший эффективность интраперитонеальной химиотерапии в отношении эпителиального рака яичников в сочетании с BRCA-мутацией [18]. Применение HIPEC при распространенном раке яичников было отражено в ряде исследований W.J.van Driel ( 2018 На Вопросы онкологии / Oncology issues При выполнении операции у всех пациенток учитывали индекс перитонеального канцероматоза (PCI -peritoneal cancer index) и заполняли карты с маркировкой остаточной опухоли [32] (рис. 3).…”

Section: цитированиеunclassified

“…Схема подсчета индекса перитонеального канцероматоза по J.E.K.R. Hentzen et al (2020) [32] Интраоперационно проводили оценку полноты циторедукции, исходя из индекса перитонеального канцероматоза. В настоящей работе были использованы индексы СС (от англ.…”

Section: цитированиеunclassified

Treatment of advanced-stage ovarian cancer including combination of intra-abdominal chemotherapy

Саевец

Привалов

Важенин

et al. 2021

jour

View full text Add to dashboard Cite

Introduction. Ovarian cancer is the leading cause of death from gynecological malignancies: the one-year relative survival rate with stages 3 and 4 of the disease is 20%. The results of treatment remain unsatisfactory, which dictates the need to find new methods of treatment. The aim of the study was to evaluate the effectiveness of the use of HIIH (hyperthermic intraperitoneal intraoperative chemoperfusion, HIPEC) in patients with the diagnosis of: ovarian cancer IIIA-From the stage of the disease.Materials and methods. 117 cases of stage IIIA-C ovarian cancer treated at the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine from January 2014 to March 2021 were retrospectively studied. All patients underwent 3 cycles of neoadjuvant chemotherapy (NAPHT) according to the paclitaxel+carboplatin (PCb) scheme, followed by surgical treatment to the extent of maximum cytoreductive surgery. Two study groups were formed: 1 — cases with GIIH (N=57), 2-without GIIH (N=60). On the 14-16 day after the operation, all patients underwent 3 cycles of adjuvant chemotherapy according to the PCb scheme.Results. A significant increase in overall survival was found in the first group of patients with HIPEC. This technique allows to increase the survival rate of patients for 14 months at stage IIIA-B (p<0.05). At stage IIIC, there was no statistically significant difference in the survival rate of patients. There was a tendency to increase the survival rate by 5 months (p>0.05), which is associated with the pronounced prevalence of the tumor process and the technical impossibility of removing the tumor. Discussion. The concentration of drugs in the abdominal cavity and in the blood plasma significantly differs due to the functioning of the peritoneal-plasma barrier, which leads to a lower toxicity in comparison with systemic chemotherapy, and therefore allows you to give a large dose of the drug with fewer adverse events, and the fact of hyperthermia (42°C) has a positive effect on the effectiveness of intraperitoneal chemotherapy. To date, this method has not been included in the clinical recommendations on the territory of the Russian Federation, but data from foreign literature, including randomized trials, have shown the high effectiveness of this method.Conclusion. The results obtained in the course of our study demonstrate the effectiveness of this technique, in the form of an increase in overall and relapse-free survival with acceptable toxicity.

show abstract

Delta peritoneal cancer index (ΔPCI): A new dynamic prognostic parameter for survival in patients with colorectal peritoneal metastases

Cited by 4 publications

References 46 publications

Effective Strategies to Predict Survival of Colorectal Peritoneal Metastases Patients Eligible for Cytoreductive Surgery and HIPEC

Effective Strategies to Predict Survival of Colorectal Peritoneal Metastases Patients Eligible for Cytoreductive Surgery and HIPEC

Determination of whether HIPEC is beneficial in patients with synchronous peritoneal and liver metastases from colorectal cancer (Review)

Treatment of advanced-stage ovarian cancer including combination of intra-abdominal chemotherapy

Contact Info

Product

Resources

About